Novo Nordisk expects lack of Wegovy doses to continue until H2 2022

Issues at a sub-contractor have meant that Novo Nordisk only has a limited supply of obesity drug Wegovy in its lowest doses available until the second half of 2022. (Corrected)

Photo: Stine Tidsvilde

(Corrected at 9:40 to clarify the extent of the supply issues)

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs